Potent interaction of flavopiridol with MRP1
- PMID: 10496352
- PMCID: PMC2362861
- DOI: 10.1038/sj.bjc.6690687
Potent interaction of flavopiridol with MRP1
Abstract
The multidrug resistance protein 1 (MRP1) is an ATP-dependent transport protein for organic anions, as well as neutral or positively charged anticancer agents. In this study we show that flavopiridol, a synthetic flavonoid currently studied in phase 1 trials for its antiproliferative characteristics, interacts with MRP1 in a potent way. Flavopiridol, as well as other (iso)flavonoids stimulate the ATPase activity of MRP1 in a dose-dependent way at low micromolar concentrations. A new specific monoclonal antibody against MRP1 (MIB6) inhibits the (iso)flavonoid-induced ATPase activity of plasma membrane vesicles prepared from the MRP1 overexpressing cell line GLC4/ADR. The accumulation of daunorubicin in GLC4/ADR cells is increased by flavopiridol and by other non-glycosylated (iso)flavonoids that interact with MRP1 ATPase activity. However, flavopiridol is the only tested compound that affects the daunorubicin accumulation when present at concentrations below 1 microM. Glycosylated (iso)flavonoids do not affect MRP1-mediated transport or ATPase activity. Finally, MRP1 overexpressing and transfected cells are resistant to flavopiridol, but not to other (iso)flavonoids tested. These findings may be of relevance for the development of anticancer therapies with flavopiridol.
Similar articles
-
Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein.FEBS Lett. 1997 Aug 18;413(2):344-8. doi: 10.1016/s0014-5793(97)00940-x. FEBS Lett. 1997. PMID: 9280310
-
ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1.Br J Pharmacol. 1999 Feb;126(3):681-8. doi: 10.1038/sj.bjp.0702360. Br J Pharmacol. 1999. PMID: 10188979 Free PMC article.
-
Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids.Mol Pharmacol. 2001 May;59(5):1171-80. doi: 10.1124/mol.59.5.1171. Mol Pharmacol. 2001. PMID: 11306701
-
[Flavopiridol, a cyclin-dependent kinase inhibitor].Bull Cancer. 2000 Oct;87(10):697-701. Bull Cancer. 2000. PMID: 11084532 Review. French. No abstract available.
-
Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4270s-4275s. doi: 10.1158/1078-0432.CCR-040020. Clin Cancer Res. 2004. PMID: 15217973 Review.
Cited by
-
A critical review on modulators of Multidrug Resistance Protein 1 in cancer cells.PeerJ. 2022 Jan 5;10:e12594. doi: 10.7717/peerj.12594. eCollection 2022. PeerJ. 2022. PMID: 35036084 Free PMC article. Review.
-
Personalized medicine in breast cancer: pharmacogenomics approaches.Pharmgenomics Pers Med. 2019 May 27;12:59-73. doi: 10.2147/PGPM.S167886. eCollection 2019. Pharmgenomics Pers Med. 2019. PMID: 31213877 Free PMC article. Review.
-
Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.Clin Pharmacokinet. 2004;43(15):1127-56. doi: 10.2165/00003088-200443150-00005. Clin Pharmacokinet. 2004. PMID: 15568891 Review.
-
Perturbation of the lipid phase of a membrane is not involved in the modulation of MRP1 transport activity by flavonoids.Cell Mol Biol Lett. 2009;14(2):199-221. doi: 10.2478/s11658-008-0044-3. Epub 2008 Nov 19. Cell Mol Biol Lett. 2009. PMID: 19020811 Free PMC article.
-
Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol.Int J Mol Med. 2014 Nov;34(5):1249-56. doi: 10.3892/ijmm.2014.1930. Epub 2014 Sep 11. Int J Mol Med. 2014. PMID: 25216351 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials